RESUMO
Aim: This study aims to evaluate the effectiveness and safety of teneligliptin when switched from other gliptins in patients notcontrolled on oral antidiabetic drugs in Type 2 diabetes mellitus (T2DM).Methodology: Data of T2DM patients who were switched from other gliptins to teneligliptin uncontrolled by dual or triple drugtherapy. Data of at least 3 months were collected from hospital records and analyzed. Efficacy was evaluated by the changesin fasting blood sugar (FBS), postprandial blood sugar (PPBS), and hemoglobin A1c (HbA1c) from the baseline.Results: A total of 97 patients’ data were collected and were analyzed. The mean age of the patients was 59.9 years andmean duration of diabetes was 16 years. Hypertension (61.9%) was the common comorbid condition with diabetes. Sitagliptinwas most prescribed dipeptidyl peptidase-4 (DPP-4) inhibitors with 65 (67%) patients with a mean dose of 88.5 mg, followedby vildagliptin with 10 (10.3%) patients was prescribed with a mean dose of 95 mg. Metformin and glimepiride were the mostcommon combination used with these DPP-4 inhibitors 91 (93.8%) patients and 69 patients (71.1%) were prescribed, respectively.There was a significant reduction in FBS, PPBS, and HbA1c from the baseline with a difference of 45 mg/dL, 102 mg/dL, and1.6%, respectively, after switching to teneligliptin from other gliptins. Teneligliptin was well tolerated and no serious adverseevents were reported.Conclusion: Teneligliptin was effective in significantly reducing FBS, PPBS, and HbA1c when switching from other gliptins inT2DM patients not controlled with other antidiabetic agents. The drug was well tolerated and no serious adverse events werereported.